LATEST NEWS

Latest News

Latest news is provided by our trusted partners at MJH Life Sciences® and its brands, and is not a publication of WAHO.

New Regimen Protects Against Cancer Relapse, Graft-Versus-Host Disease After Donor Stem Cell Transplant

March 24, 2026

Roswell Park Comprehensive Cancer Center

Study led by Roswell Park’s Dr. Brian Betts and Dr. Shernan Holtan highlighted in Blood Advances.

Selinexor Plus Ruxolitinib Hits SVR Primary End Point in Myelofibrosis

March 24, 2026

Chris Ryan

Selinexor plus ruxolitinib met the SVR co-primary end point but missed the symptom score end point in the phase 3 SENTRY trial in myelofibrosis.

Early Intervention and Individualization Are Key to Improving Kidney Cancer Outcomes

March 24, 2026

Kyle Doherty

Neil Mendhiratta, MD, MS, and Toni K. Choueiri, MD, discuss the current and future treatment landscape of kidney cancer during Kidney Cancer Awareness Month.

Rapcabtagene Autoleucel Yields Efficacy, Safety in R/R B-ALL

March 24, 2026

Riley Kandel

Rapcabtagene autoleucel exhibited promising response and safety data in relapsed or refractory B-cell acute lymphoblastic leukemia.

Investigators Tease Out Dermatologic AEs With Tebentafusp in Metastatic Uveal Melanoma

March 23, 2026

Caroline Seymour

Tebentafusp use was associated with frequent dermatologic AEs, with desquamation and hypopigmentation observed in non-White patients in a real-world analysis.

Liso-Cel Drives Durable Longer-Term Benefit in R/R Follicular Lymphoma

March 23, 2026

Chris Ryan

Updated data from TRANSCEND FL showed durable efficacy outcomes with liso-cel in relapsed/refractory follicular lymphoma.

Adjuvant Pembrolizumab Maintains Benefit-Risk Profile in KEYNOTE-716 Analysis for High-Risk Stage II Melanoma

March 23, 2026

Caroline Seymour

Sensitivity analyses accounting for new primary melanoma did not diminish the RFS benefit favoring adjuvant pembrolizumab vs placebo in high-risk stage II melanoma.

Sunvozertinib Monotherapy Bests Platinum-Doublet Chemotherapy in EGFR Exon 20+ NSCLC

March 23, 2026

Caroline Seymour

PFS was improved when patients with advanced EGFR exon 20 insertion–positive NSCLC received sunvozertinib vs platinum chemotherapy in the first line.

Tafasitamab-Based Regimen Nets Approval in Brazil for R/R Follicular Lymphoma

March 23, 2026

Riley Kandel

Tafasitamab has been approved by ANVISA for the treatment of relapsed or refractory follicular lymphoma.

ctDNA Assays Advance Breast Cancer MRD Detection, Prompt Critical Application Questions

March 23, 2026

Ashling Wahner

Marla D. Lipsyc-Sharf, MD, discusses the evolving role of MRD ctDNA testing in breast cancer management and aiding in early detection of disease recurrence.

Mayo Clinic Study Demonstrates Safety, Feasibility of Delivering Chemotherapy at Home

March 23, 2026

Mayo Clinic

Chemo therapy delivered in the home of patients has shown feasibility and safety according to researchers at Mayo Clinic

Delayed irAEs After Immunotherapy Demand Long-Term Vigilance and New Care Models in Melanoma

March 22, 2026

Caroline Seymour

Limited knowledge of long-term irAEs points to the need for more concentrated research regarding optimal post-immunotherapy toxicity management.

Five Under 5: Top Oncology Videos for the Week of 3/15

March 22, 2026

OncLive Staff

The top 5 OncLive TV videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, lung cancer, breast cancer, and prostate cancer.

The OncFive: Top Oncology Articles for the Week of 3/15

March 21, 2026

OncLive Staff

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

Pathologists Remain Central to Lung Cancer Care as Biomarker-Directed Therapy Grows

March 20, 2026

Caroline Seymour

Pathologists play a key role in lung cancer care, from biomarker testing to tissue triage.